Cancer-associated_cachexia

Circulating granulocyte colony-stimulating factor as a sex-unbiased global marker of lung and colorectal cancer cachexia pre-clinical models.

Cancer cachexia, affecting up to 80% of patients with advanced cancer, is characterized by metabolic and inflammatory dysregulation driven by tumour- and host-derived factors. Although cytokines are central to cachexia pathogenesis, their circulating profiles and transcriptional relevance across models and...

🗓️ 2026-08-13
📰 Publication: Experimental Physiology
Read MoreCirculating granulocyte colony-stimulating factor as a sex-unbiased global marker of lung and colorectal cancer cachexia pre-clinical models.

Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.

Cancer cachexia is a life-threatening wasting syndrome that can be driven by tumor-derived GDF15 signaling through the brainstem-restricted receptor GFRAL. Despite its clinical importance, central genetic interventions targeting this axis remain limited. Here, we develop a potent antisense oligonucleotide (Gfral-ASO,...

🗓️ 2026-07-28
📰 Publication: Cell Reports Medicine
Read MoreTherapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.

Pre-clinical cancer cachexia causes glucose hypermetabolism prior to overt weight loss.

PURPOSE

Cancer cachexia is a life-threatening complication of advanced malignancies, driven by profound systemic metabolic reprogramming and anorexia. Insulin action is markedly impaired in patients with cancer and may contribute directly to cachexia pathogenesis. However, the interplay between weight loss, food...

🗓️ 2026-07-18
📰 Publication: Molecular Metabolism
Read MorePre-clinical cancer cachexia causes glucose hypermetabolism prior to overt weight loss.

Sex-divergent skeletal muscle remodeling emerges early in cancer cachexia.

Cancer cachexia is characterised by progressive skeletal muscle wasting and dysfunction, yet the early events that precede overt muscle wasting remain poorly defined. Here, we utilised a time-coursed C26 carcinoma model in male and female mice to define the pre-cachectic...

🗓️ 2026-07-17
📰 Publication: American Journal Of Physiology-Cell Physiology
Read MoreSex-divergent skeletal muscle remodeling emerges early in cancer cachexia.

Pancreatic cancer cachexia promotes cardiac dysfunction through altered adrenergic signalling in the heart.

Cancer cachexia is a metabolic syndrome commonly observed in patients with pancreatic ductal adenocarcinoma (PDAC), characterized by wasting of skeletal and cardiac muscle. This condition is associated with the neurohormonal stress response and activation of the sympathetic nervous system. However...

🗓️ 2026-07-17
📰 Publication: Journal Of Physiology-London
Read MorePancreatic cancer cachexia promotes cardiac dysfunction through altered adrenergic signalling in the heart.

Differential impact of cancer- and chemotherapy-induced cachexia: a comparative analysis in a pre-clinical model of colorectal cancer by biological sex.

Cancer cachexia is a wasting condition characterized by muscle loss and reduced quality of life in cancer patients. Although biological sex differences in the progression of cancer cachexia have been increasingly recognized, their role during chemotherapy-treated cancer cachexia remains largely...

🗓️ 2026-07-15
📰 Publication: American Journal Of Physiology-Endocrinology And Metabolism
Read MoreDifferential impact of cancer- and chemotherapy-induced cachexia: a comparative analysis in a pre-clinical model of colorectal cancer by biological sex.

Li-ginseng powder alleviates cancer cachexia in mice by regulating the ubiquitin-proteasome pathway and reducing inflammation.

BACKGROUND

As a debilitating syndrome, cancer cachexia (CC) manifests as ongoing weight reduction and skeletal muscle atrophy, which severely compromise patients' well-being and life expectancy, with no approved treatment available to date. Rare ginsenosides such as Rh2, Rg5, Rk1, and Rh4...

🗓️ 2026-07-03
📰 Publication: Journal Of Ginseng Research
Read MoreLi-ginseng powder alleviates cancer cachexia in mice by regulating the ubiquitin-proteasome pathway and reducing inflammation.

A dietary switch promotes sensory neuron-dependent cancer-associated cachexia.

Sickness behaviors are common in cancer-associated cachexia and affect up to half of lung cancer patients. We demonstrate that among the most common cancer mutations, loss of liver kinase B1 (Lkb1) promotes the development of cachexia in preclinical models of...

🗓️ 2026-07-02
📰 Publication: Science
Read MoreA dietary switch promotes sensory neuron-dependent cancer-associated cachexia.

An immunological panacea for cancer-related cachexia.

Cancer cachexia, responsible for up to 30% of cancer deaths, has transitioned conceptually from a mere nutritional deficit into a highly coordinated, multi-organ immunometabolic network that systematically dismantles host homeostasis. This review synthesizes the paradigm-shifting discoveries that position the immune...

🗓️ 2026-06-25
📰 Publication: Trends In Cancer
Read MoreAn immunological panacea for cancer-related cachexia.

Combination Therapy with Bisoprolol and Tissue Protective Molecule ARA 284 Is Cardio-Protective and Improves Survival in Experimental Cancer Cachexia.

BACKGROUND

Cancer cachexia is a serious condition during the last stages of the disease, which is characterized by the loss of muscle and fat mass in patients with cancer. There are no effective treatments for cancer cachexia, and new treatment interventions...

🗓️ 2026-06-25
Read MoreCombination Therapy with Bisoprolol and Tissue Protective Molecule ARA 284 Is Cardio-Protective and Improves Survival in Experimental Cancer Cachexia.

Autophagy in cancer cachexia: From mechanisms to therapeutic opportunities.

Cancer cachexia is a multifactorial syndrome characterized by body weight loss, muscle wasting, and systemic metabolic alterations, significantly contributing to patient morbidity and mortality. A key feature of cachexia is the excessive degradation of muscle proteins and mitochondria, largely mediated...

🗓️ 2026-06-11
Read MoreAutophagy in cancer cachexia: From mechanisms to therapeutic opportunities.

MOTS-c partially protects against skeletal muscle deterioration in C26 cachexia.

BACKGROUND

Cancer cachexia is a multifactorial metabolic syndrome marked by progressive skeletal muscle loss, reduced function, and increased mortality. Mitochondrial dysfunction is a key driver of this phenotype. MOTS-c, a mitochondrial-derived peptide that regulates metabolic homeostasis and mimics exercise signaling, may...

🗓️ 2026-06-10
Read MoreMOTS-c partially protects against skeletal muscle deterioration in C26 cachexia.

Lowered Abundance of Gut Bacteriophage Species Is Associated With Human Cancer Cachexia.

BACKGROUND

Cancer cachexia exemplifies a high medical need condition without effective treatment. Recent studies implicated bacterial gut microbiome alterations to cancer cachexia. Whether the gut bacteriophage profile, an important microbiome component for health and disease, is also related to cancer cachexia...

🗓️ 2026-06-08
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLowered Abundance of Gut Bacteriophage Species Is Associated With Human Cancer Cachexia.

PEBP4 alleviates muscle wasting in lung cancer cachexia via KEAP1-NRF2-mediated redox homeostasis.

Cancer-associated cachexia (CAC) is a multifactorial metabolic syndrome characterized by progressive skeletal muscle wasting. However, the molecular link between tumor metabolic stress and muscle degradation remains elusive. Here, we identify phosphatidylethanolamine-binding protein 4 (PEBP4) as a key regulator of muscle...

🗓️ 2026-06-04
📰 Publication: Cell Death & Disease
Read MorePEBP4 alleviates muscle wasting in lung cancer cachexia via KEAP1-NRF2-mediated redox homeostasis.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!